XML 41 R29.htm IDEA: XBRL DOCUMENT
v3.21.2

Segment Information (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2021
Segment Reporting [Abstract] |
Schedule of Operations by Reportable Segment | Approximate information concerning the Company’s operations by reportable segment for the three and nine months ended September 30, 2021, and 2020 is as follows. The Company relies on intersegment cooperation and management does not represent that these segments, if operated independently, would report the results contained herein: Schedule of Operations by Reportable Segment
Three Months Ended September 30, 2021 |  | Packaging and Printing |  | Investment Banking |  |  | Direct Marketing |  |  | Biohealth Group |  |  | Securities |  |  | Corporate |  |  | Total |
Revenue |  | $ | 3,416,000 |  | $ | - |  |  | $ | 966,000 |  |  | $ | - |  |  | $ | 184,000 |  |  | $ | - |  |  | $ | 4,566,000 |
Depreciation and amortization |  |  | 152,000 |  |  | - |  |  |  | 100,000 |  |  |  | 278,000 |  |  |  | 135,000 |  |  |  | 74,000 |  |  |  | 739,000 |
Interest expense |  |  | 11,000 |  |  | - |  |  |  | - |  |  |  | - |  |  |  | 37,000 |  |  |  | (17,000 | ) |  |  | 31,000 |
Stock based compensation |  |  | 1,000 |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | 12,000 |  |  |  | 13,000 |
Net income (loss) from continuing operations |  |  | 358,000 |  |  | 64,000 |  |  |  | (1,304,000 | ) |  |  | (647,000 | ) |  |  | (835,000 | ) |  |  | (4,311,000 | ) |  |  | (6,675,000 | )
Capital expenditures |  |  | 1,399,000 |  |  | - |  |  |  | - |  |  |  | - |  |  |  | 186,000 |  |  |  | 55,000 |  |  |  | 1,640,000 |
Identifiable assets |  |  | 24,752,000 |  |  | 60,388,000 |  |  |  | 43,695,000 |  |  |  | 55,848,000 |  |  |  | 11,376,000 |  |  |  | 23,017,000 |  |  |  | 219,076,000 |
Three Months Ended September 30,2020 |  | Packaging and Printing |  |  | Direct Marketing |  |  | Biohealth Group |  |  | Securities |  |  | Corporate |  |  | Total |
Revenue |  | $ | 2,971,000 |  |  | $ | 715,000 |  |  | $ | - |  |  | $ | - |  |  | $ | - |  |  | $ | 3,686,000 |
Depreciation and amortization |  |  | 165,000 |  |  |  | 1,000 |  |  |  | - |  |  |  | - |  |  |  | 78,000 |  |  |  | 244,000 |
Interest expense |  |  | 24,000 |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | 5,000 |  |  |  | 29,000 |
Stock based compensation |  |  | 3,000 |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | 125,000 |  |  |  | 128,000 |
Net income (loss) from continuing operations |  |  | 136,000 |  |  |  | (1,139,000 | ) |  |  | - |  |  |  | - |  |  |  | 6,185,000 |  |  |  | 5,182,000 |
Capital expenditures |  |  | 1,000 |  |  |  | 1,000 |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | 2,000 |
Identifiable assets |  |  | 10,013,000 |  |  |  | 1,809,000 |  |  |  | - |  |  |  | - |  |  |  | 68,305,000 |  |  |  | 80,127,000 |
Nine Months Ended September 30, 2021 |  | Packaging and Printing |  | Investment Banking |  |  | Direct Marketing |  |  | Biohealth Group |  |  | Securities |  |  | Corporate |  |  | Total |
Revenue |  | $ | 10,652,000 |  | $ | - |  |  | $ | 2,382,000 |  |  | $ | - |  |  | $ | 184,000 |  |  | $ | - |  |  | $ | 13,218,000 |
Depreciation and amortization |  |  | 459,000 |  |  | - |  |  |  | 419,000 |  |  |  | 835,000 |  |  |  | 134,000 |  |  |  | 228,000 |  |  |  | 2,075,000 |
Interest expense |  |  | 49,000 |  |  | - |  |  |  | 2,000 |  |  |  | 1,000 |  |  |  | 87,000 |  |  |  | 18,000 |  |  |  | 157,000 |
Stock based compensation |  |  | 2,000 |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | 40,000 |  |  |  | 42,000 |
Net income (loss) from continuing operations |  |  | 641,000 |  |  | 64,000 |  |  |  | (9,088,000 | ) |  |  | (1,955,000 | ) |  |  | (1,066,000 | ) |  |  | (10,058,000 | ) |  |  | (21,462,000 | )
Capital expenditures |  |  | 2,621,000 |  |  | - |  |  |  | 6,000 |  |  |  | - |  |  |  | 6,750,000 |  |  |  | 4,000 |  |  |  | 9,381,000 |
Identifiable assets |  |  | 24,752,000 |  |  | 60,388,000 |  |  |  | 43,695,000 |  |  |  | 55,848,000 |  |  |  | 11,376,000 |  |  |  | 23,017,000 |  |  |  | 219,076,000 |
Nine Months Ended September 30,2020 |  | Packaging and Printing |  |  | Direct Marketing |  |  | Biohealth Group |  |  |  | Securities |  |  | Corporate |  |  | Total |
Revenue |  | $ | 8,409,000 |  |  | $ | 1,793,000 |  |  | $ | - |  | $ |  | $ | - |  |  |  | - |  |  | $ | 10,202,000 |
Depreciation and amortization |  |  | 584,000 |  |  |  | 1,000 |  |  |  | - |  |  |  |  | - |  |  |  | 227,000 |  |  |  | 812,000 |
Interest expense |  |  | 79,000 |  |  |  | - |  |  |  | - |  |  |  |  | - |  |  |  | 23,000 |  |  |  | 102,000 |
Stock based compensation |  |  | 11,000 |  |  |  | - |  |  |  | - |  |  |  |  | - |  |  |  | 170,000 |  |  |  | 181,000 |
Net income (loss) from continuing operations |  |  | 222,000 |  |  |  | (960,000 | ) |  |  | - |  |  |  |  | - |  |  |  | 4,249,000 |  |  |  | 3,511,000 |
Capital expenditures |  |  | 91,000 |  |  |  | 1,000 |  |  |  | - |  |  |  |  | - |  |  |  | 1,000 |  |  |  | 93,000 |
Identifiable assets |  |  | 10,013,000 |  |  |  | 1,809,000 |  |  |  | - |  |  |  |  | - |  |  |  | 68,305,000 |  |  |  | 80,127,000 |
Schedule of Disaggregation of Revenue | The following tables disaggregate our business segment revenues by major source: Schedule of Disaggregation of Revenue Printed Products Revenue Information:
Three months ended September 30, 2021 |  |  |
Packaging Printing and Fabrication |  | $ | 3,373,000 |
Commercial and Security Printing |  |  | 43,000 |
Total Printed Products |  | $ | 3,416,000 |
Three months ended September 30, 2020 |  |  |
Packaging Printing and Fabrication |  | $ | 2,568,000 |
Commercial and Security Printing |  |  | 403,000 |
Total Printed Products |  | $ | 2,971,000 |
Nine months ended September 30, 2021 |  |  |
Packaging Printing and Fabrication |  | $ | 10,428,000 |
Commercial and Security Printing |  |  | 224,000 |
Total Printed Products |  | $ | 10,652,000 |
Nine months ended September 30, 2020 |  |  |
Packaging Printing and Fabrication |  | $ | 7,635,000 |
Commercial and Security Printing |  |  | 774,000 |
Total Printed Products |  | $ | 8,409,000 |
Direct Marketing
Three months ended September 30, 2021 |  |  |
Direct Marketing Internet Sales |  | $ | 966,000 |
Total Direct Marketing |  | $ | 966,000 |
Three months ended September 30, 2020 |  |  |
Direct Marketing Internet Sales |  | $ | 715,000 |
Total Direct Marketing |  | $ | 715,000 |
Nine months ended September 30, 2021 |  |  |
Direct Marketing Internet Sales |  | $ | 2,382,000 |
Total Direct Marketing |  | $ | 2,382,000 |
Nine months ended September 30, 2020 |  |  |
Direct Marketing Internet Sales |  | $ | 1,793,000 |
Total Direct Marketing |  | $ | 1,793,000 |
Securities
Three months ended September 30, 2021 |  |  |
Rental Income |  | $ | 184,000 |
Total Rental Income |  | $ | 184,000 |
Three months ended September 30, 2020 |  |  |  |
Rental Income |  | $ | - |
Total Rental Income |  | $ | - |
Nine months ended September 30, 2021 |  |  |
Rental Income |  | $ | 184,000 |
Total Rental Income |  | $ | 184,000 |
Nine months ended September 30, 2020 |  |  |  |
Rental Income |  | $ | - |
Total Rental Income |  | $ | - |

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration